Dermata TherapeuticsDRMA
13F holders, Q1 2025 (March 31)8holders +2
2new positions
0sold out
$1.08avg. 13F price*
At the end of Q1 2025, 8 institutions reported holding Dermata Therapeutics Inc. (DRMA) in their 13F filings, up 2 from Q4 2024. 2 opened new positions and 0 sold out. The largest holders were Armistice Capital, LLC ($444K), UBS Group AG ($76K) and Geode Capital Management, LLC ($22K).
- Company
- Dermata Therapeutics Inc.
- CUSIP
- 249845405
- Latest filing quarter
- Q2 2025
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $36K |
| Exits | 0 | $0 |
All 13F filers, Q4 2024 → Q1 2025: 473,029 shares bought and 45 shares sold, net +472,984 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 8 holders
| Armistice Capital, LLC | 0.01% | Add +1411.0% | 411,000 | $444K |
| UBS Group AG | 0.00% | Add +406.6% | 70,290 | $76K |
| Geode Capital Management, LLC | 0.00% | New | 20,406 | $22K |
| Jones Financial Companies LLLP | 0.00% | New | 12,000 | $14K |
| Wells Fargo & Company | 0.00% | Reduce -2.2% | 2,000 | $2K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +28.8% | 1,796 | $2K |
| SBI Securities Co., Ltd. | 0.00% | No change | 1,000 | $1K |
| Bank of America Corp. | 0.00% | Add +31.3% | 21 | $23 |
"% of holder's portfolio" is DRMA's weight in each manager's 13F, not the share of Dermata Therapeutics Inc. the manager owns.